Marinus Pharmaceuticals

MRNS50

Penny Stock

$1.39arrow_drop_down0.71%-$0.01

Penny Stock

MRNS50

$1.39

arrow_drop_down0.71%-$0.01

Penny Stock

Performance History

Key Stats
Open	$1.42
Prev. Close	$1.40
EPS	-2.66
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$77.11M
PE Ratio	-

	LOW	HIGH
Day Range	1.38	1.44
52 Week Range	1.05	11.26

Ratios







EPS	-2.66

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Marinus Pharmaceuticals (MRNS)

Marinus Pharmaceuticals Inc (MRNS) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapeutics to treat epilepsy and other neurological disorders. The company's lead product candidate is ganaxolone, a selective, synthetic neurosteroid, which is being investigated for the treatment of various types of epilepsy, including refractory status epilepticus (RSE) and postpartum depression (PPD).

Ganaxolone has shown promising results in clinical trials, demonstrating its potential to reduce seizure activity and improve seizure control in patients with epilepsy. RSE is a life-threatening condition characterized by prolonged seizures that do not respond to initial treatment, while PPD is a mood disorder that can occur after childbirth.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Scott N. Braunstein M.D.
Headquarters: Radnor
Employees: 151
Exchange: NASDAQ

add Marinus Pharmaceuticals to watchlist

Keep an eye on Marinus Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Marinus Pharmaceuticals 's (MRNS) price per share?

The current price per share for Marinus Pharmaceuticals (MRNS) is $1.39. The stock has seen a price change of -$0.01 recently, indicating a -0.71% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Marinus Pharmaceuticals (MRNS)?

For Marinus Pharmaceuticals (MRNS), the 52-week high is $11.26, which is 710.07% from the current price. The 52-week low is $1.05, the current price is 32.38% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Marinus Pharmaceuticals (MRNS) a growth stock?

Marinus Pharmaceuticals (MRNS) has shown an average price growth of 0.41% over the past three years. It has received a score of 11 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Marinus Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Marinus Pharmaceuticals (MRNS) stock price performance year to date (YTD)?

As of the latest data, Marinus Pharmaceuticals (MRNS) has a year-to-date price change of -86.63%. Over the past month, the stock has experienced a price change of 11.2%. Over the last three months, the change has been -9.74%. Over the past six months, the figure is -84.29%. Looking at a longer horizon, the five-year price change stands at -80.03%.

help

Is Marinus Pharmaceuticals (MRNS) a profitable company?

Marinus Pharmaceuticals (MRNS) has a net income of -$141.4M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 91.98% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -375.94% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $30.99M, with a revenue growth rate of 21.63%, providing insight into the company's sales performance and growth. The gross profit is $28.5M. Operating income is noted at -$131.48M. Furthermore, the EBITDA is -$128.66M.

help

What is the market capitalization of Marinus Pharmaceuticals (MRNS)?

Marinus Pharmaceuticals (MRNS) has a market capitalization of $77.12M. The average daily trading volume is 349.51K, indicating the stock's liquidity and investor engagement.

News

MATERNAL MENTAL HEALTH

POSTPARTUM DEPRESSION

MENTAL HEALTH SERVICES

8/14/2024

Global Maternal Mental Health Market to Exhibit Growth at Tremendous CAGR of ~15% by 2030 | DelveInsight

MARINUS PHARMACEUTICALS

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS

MARINUS PHARMACEUTICALS

CLASS ACTION LAWSUIT

RAISE TRIAL

REFRACTORY STATUS EPILEPTICUS

COST-CUTTING MEASURES

7/30/2024

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)

MARINUS PHARMACEUTICALS

SECURITIES CLASS ACTION

RAISE TRIAL

RAISE II TRIAL

7/29/2024

MRNS DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Marinus Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNS

MARINUS PHARMACEUTICALS

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Humana, and Lamb Weston and Encourages Investors to Contact the Firm